JPMorgan analysts predict a strong uptake for Novartis's var...
JPMorgan analysts predict a strong uptake for Novartis's various treatments to boost the company's top line, with cost savings from restructuring aiding the bottom line. Morgan Stanley analysts note Novartis's need for external innovation to meet long-term growth ambitions.
![](https://pubimg-10000538.picsh.myqcloud.com/202205090000028988456dbe14b.jpg)
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment